Amgen 3Q profit jumps 24 pct. on stronger sales

October 22, 2013 by Linda A. Johnson

Biotech drugmaker Amgen Inc. said Tuesday that its third-quarter profit jumped 24 percent, trouncing analysts' expectations, as sales of more than a half-dozen of its drugs increased by double digits.

The strong performance in the quarter ending Sept. 30 came just before Amgen closed its $9.7 billion purchase of cancer drug maker Onyx Pharmaceuticals on Oct. 1—part of Amgen's strategy to expand beyond its medicines for easing side effects of some cancer treatments and enter the market for pricey cancer drugs.

It's also just begun joint ventures to sell colorectal cancer drug Vectibix in China and to develop and then sell five medicines in Japan. Japan is the world's second-biggest medicine market, after the U.S., and China is spending more on health care, making its huge and aging population a growth target for most pharmaceutical and biotech companies.

Amgen, which sells arthritis treatment Enbrel and Prolia for osteoporosis, said net income was $1.37 billion, or $1.79 per share, up from $1.11 billion, or $1.41 per share, a year earlier.

The Thousand Oaks, California-based company said earnings were $1.94 per share excluding one-time items, mainly costs related to acquisitions, efficiency efforts and issuing stock options. Analysts were expecting $1.76 per share.

Amgen's stock rose 79 cents to $117 in after-hours trading after rising $2.57, or 2.3 percent, to $116.21 during the regular trading session.

Amgen beat that handily due to a decline in its tax rate, a $155 million U.S. government order for Neupogen for boosting infection-fighting white blood cells, and very strong sales of nearly all its drugs.

Revenue was up 10 percent at $4.75 billion, topping the $4.6 billion analysts expected.

The company also raised the lower end of its 2013 profit forecast by a nickel and now expects $7.35 to $7.45 per share.

"We delivered excellent operating performance this quarter," chief executive Robert Bradway said in a statement. "We also delivered excellent strategic progress."

Explore further: Amgen 2Q net dips on higher research, other costs (Update)

Related Stories

Amgen 2Q net dips on higher research, other costs (Update)

July 30, 2013
Amgen Inc. said Tuesday that its second-quarter profit dipped 1 percent as higher spending on research, production and other items offset rising sales of its medicines.

Amgen 4Q profit drops 16 pct. on higher spending

January 23, 2013
Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...

Generic competition cuts Merck's Q1 sales, profit

May 1, 2013
Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.

Recommended for you

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.